Search Results - "Fearon, Douglas"

T cell exclusion, immune privilege, and the tumor microenvironment by Joyce, Johanna A., Fearon, Douglas T.

“…Effective immunotherapy promotes the killing of cancer cells by cytotoxic T cells. This requires not only that cancer-specific T cells be generated, but also…”
Get full text

The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance by Fearon, Douglas T

“…The fibroblastic element of the tumor microenvironment has been of great interest to cancer biologists but less so to cancer immunologists. Yet, the sharing of…”
Get more information

Intratumoral NKT cell accumulation promotes antitumor immunity in pancreatic cancer by Li, Jiayun, Moresco, Philip, Fearon, Douglas T

“…Pancreatic ductal adenocarcinoma (PDA) is a potentially lethal disease lacking effective treatments. Its immunosuppressive tumor microenvironment (TME) allows…”
Get full text

Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity by Flint, Thomas R., Janowitz, Tobias, Connell, Claire M., Roberts, Edward W., Denton, Alice E., Coll, Anthony P., Jodrell, Duncan I., Fearon, Douglas T.

“…In patients with cancer, the wasting syndrome, cachexia, is associated with caloric deficiency. Here, we describe tumor-induced alterations of the host…”
Get full text

Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases by Pommier, Arnaud, Anaparthy, Naishitha, Memos, Nicoletta, Kelley, Z Larkin, Gouronnec, Alizée, Yan, Ran, Auffray, Cédric, Albrengues, Jean, Egeblad, Mikala, Iacobuzio-Donahue, Christine A, Lyons, Scott K, Fearon, Douglas T

“…The majority of patients with pancreatic ductal adenocarcinoma (PDA) develop metastatic disease after resection of their primary tumor. We found that livers…”
Get full text

AMD3100/Plerixafor overcomes immune inhibition by the CXCL12–KRT19 coating on pancreatic and colorectal cancer cells by Fearon, Douglas T., Janowitz, Tobias

“…Summary A recent Phase 1 clinical study of the immunological effects of inhibiting the chemokine receptor, CXCR4, in patients with pancreatic ductal…”
Get full text

Understanding the tumor immune microenvironment (TIME) for effective therapy by Binnewies, Mikhail, Roberts, Edward W., Kersten, Kelly, Chan, Vincent, Fearon, Douglas F., Merad, Miriam, Coussens, Lisa M., Gabrilovich, Dmitry I., Ostrand-Rosenberg, Suzanne, Hedrick, Catherine C., Vonderheide, Robert H., Pittet, Mikael J., Jain, Rakesh K., Zou, Weiping, Howcroft, T. Kevin, Woodhouse, Elisa C., Weinberg, Robert A., Krummel, Matthew F.

“…The clinical successes in immunotherapy have been both astounding and at the same time unsatisfactory. Countless patients with varied tumor types have seen…”
Get full text

Distinct fibroblast subsets drive inflammation and damage in arthritis by Croft, Adam P., Campos, Joana, Jansen, Kathrin, Turner, Jason D., Marshall, Jennifer, Attar, Moustafa, Savary, Loriane, Wehmeyer, Corinna, Naylor, Amy J., Kemble, Samuel, Begum, Jenefa, Dürholz, Kerstin, Perlman, Harris, Barone, Francesca, McGettrick, Helen M., Fearon, Douglas T., Wei, Kevin, Raychaudhuri, Soumya, Korsunsky, Ilya, Brenner, Michael B., Coles, Mark, Sansom, Stephen N., Filer, Andrew, Buckley, Christopher D.

“…The identification of lymphocyte subsets with non-overlapping effector functions has been pivotal to the development of targeted therapies in immune-mediated…”
Get full text

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer by Feig, Christine, Jones, James O., Kraman, Matthew, Wells, Richard J. B., Deonarine, Andrew, Chan, Derek S., Connell, Claire M., Roberts, Edward W., Qi Zhao, Caballero, Otavia L., Teichmann, Sarah A., Janowitz, Tobias, Jodrell, Duncan I., Tuveson, David A., Fearon, Douglas T.

“…An autochthonous model of pancreatic ductal adenocarcinoma (PDA) permitted the analysis of why immunotherapy is ineffective in this human disease. Despite…”
Get full text

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer by Öhlund, Daniel, Handly-Santana, Abram, Biffi, Giulia, Elyada, Ela, Almeida, Ana S, Ponz-Sarvise, Mariano, Corbo, Vincenzo, Oni, Tobiloba E, Hearn, Stephen A, Lee, Eun Jung, Chio, Iok In Christine, Hwang, Chang-Il, Tiriac, Hervé, Baker, Lindsey A, Engle, Dannielle D, Feig, Christine, Kultti, Anne, Egeblad, Mikala, Fearon, Douglas T, Crawford, James M, Clevers, Hans, Park, Youngkyu, Tuveson, David A

“…Pancreatic stellate cells (PSCs) differentiate into cancer-associated fibroblasts (CAFs) that produce desmoplastic stroma, thereby modulating disease…”
Get full text

CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response by Biasci, Daniele, Smoragiewicz, Martin, Connell, Claire M., Wang, Zhikai, Gao, Ya, Thaventhiran, James E. D., Basu, Bristi, Magiera, Lukasz, Johnson, T. Isaac, Bax, Lisa, Gopinathan, Aarthi, Isherwood, Christopher, Gallagher, Ferdia A., Pawula, Maria, Hudecova, Irena, Gale, Davina, Rosenfeld, Nitzan, Barmpounakis, Petros, Popa, Elizabeta Cristina, Brais, Rebecca, Godfrey, Edmund, Mirk, Fraz, Richards, Frances M., Fearon, Douglas T., Janowitz, Tobias, Jodrell, Duncan I.

“…Inhibition of the chemokine receptor CXCR4 in combination with blockade of the PD-1/PD-L1 T cell checkpoint induces T cell infiltration and anticancer…”
Get full text

Connecting the Metabolic and Immune Responses to Cancer by Flint, Thomas R, Fearon, Douglas T, Janowitz, Tobias

“…Separate research fields have advanced our understanding of, on the one hand, cancer immunology and, on the other hand, cachexia, the fatal tumor-induced…”
Get full text

Secondary Replicative Function of CD8⁺ T Cells That Had Developed an Effector Phenotype by Bannard, Oliver, Kraman, Matthew, Fearon, Douglas T

“…Models of the differentiation of memory CD8⁺ T cells that replicate during secondary infections differ over whether such cells had acquired effector function…”
Get full text

A framework for advancing our understanding of cancer-associated fibroblasts by Sahai, Erik, Astsaturov, Igor, Cukierman, Edna, DeNardo, David G., Egeblad, Mikala, Evans, Ronald M., Fearon, Douglas, Greten, Florian R., Hingorani, Sunil R., Hunter, Tony, Hynes, Richard O., Jain, Rakesh K., Janowitz, Tobias, Jorgensen, Claus, Kimmelman, Alec C., Kolonin, Mikhail G., Maki, Robert G., Powers, R. Scott, Puré, Ellen, Ramirez, Daniel C., Scherz-Shouval, Ruth, Sherman, Mara H., Stewart, Sheila, Tlsty, Thea D., Tuveson, David A., Watt, Fiona M., Weaver, Valerie, Weeraratna, Ashani T., Werb, Zena

“…Cancer-associated fibroblasts (CAFs) are a key component of the tumour microenvironment with diverse functions, including matrix deposition and remodelling,…”
Get full text

Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology by Nayar, Saba, Campos, Joana, Smith, Charlotte G., Iannizzotto, Valentina, Gardner, David H., Mourcin, Frédéric, Roulois, David, Turner, Jason, Sylvestre, Marvin, Asam, Saba, Glaysher, Bridget, Bowman, Simon J., Fearon, Douglas T., Filer, Andrew, Tarte, Karin, Luther, Sanjiv A., Fisher, Benjamin A., Buckley, Christopher D., Coles, Mark C., Barone, Francesca

“…Resident fibroblasts at sites of infection, chronic inflammation, or cancer undergo phenotypic and functional changes to support leukocyte migration and, in…”
Get full text

Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8⁺ T cells by Denton, Alice E., Roberts, Edward W., Linterman, Michelle A., Fearon, Douglas T.

“…Fibroblastic reticular cells (FRCs), through their expression of CC chemokine ligand (CCL)19 and CCL21, attract and retain T cells in lymph nodes (LNs), but…”
Get full text

Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-α by Kraman, Matthew, Bambrough, Paul J, Arnold, James N, Roberts, Edward W, Magiera, Lukasz, Jones, James O, Gopinathan, Aarthi, Tuveson, David A, Fearon, Douglas T

“…The stromal microenvironment of tumors, which is a mixture of hematopoietic and mesenchymal cells, suppresses immune control of tumor growth. A stromal cell…”
Get full text

Embryonic FAP + lymphoid tissue organizer cells generate the reticular network of adult lymph nodes by Denton, Alice E, Carr, Edward J, Magiera, Lukasz P, Watts, Andrew J B, Fearon, Douglas T

“…The induction of adaptive immunity is dependent on the structural organization of LNs, which is in turn governed by the stromal cells that underpin LN…”
Get full text

Cancer cell CCR2 orchestrates suppression of the adaptive immune response by Fein, Miriam R, He, Xue-Yan, Almeida, Ana S, Bružas, Emilis, Pommier, Arnaud, Yan, Ran, Eberhardt, Anaïs, Fearon, Douglas T, Van Aelst, Linda, Wilkinson, John Erby, Dos Santos, Camila O, Egeblad, Mikala

“…C-C chemokine receptor type 2 (CCR2) is expressed on monocytes and facilitates their recruitment to tumors. Though breast cancer cells also express CCR2, its…”
Get full text

Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1 by Arnold, James N, Magiera, Lukasz, Kraman, Matthew, Fearon, Douglas T

“…The depletion of tumor stromal cells that are marked by their expression of the membrane protein fibroblast activation protein-α (FAP) overcomes immune…”
Get more information